Delic Labs President and CSO Dr. Markus Roggen named to Cannabis Scientist Power List for third consecutive year

Delic Holdings Corp ("Delic" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today celebrated Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, being named to the Cannabis Scientist Power List for the third consecutive year. Dr. Markus Roggen is consistently recognized as one of the most influential figures in the processing professionals category because of his commitment to creating a body of work on cannabis research that will have a lasting effect on the industry for the better. Under Dr. Roggen's leadership, Delic Labs will transfer their expertise and experience from the cannabis sector to establish itself as the leader in psychedelic research and safety testing. The lab has received Health Canada 56 exemptions for chemistry analytics on psilocybin mushrooms; to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD; and has received psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs expects to receive within the next months a Dealer's License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes.

With the Health Canada 56 exemptions and a Dealer's License, the Company plans to implement consistent quality control standards to enhance the use of psychedelic compounds for medical purposes.